Tags: Arthritis | rheumatoid arthritis | arthritis drug | sarilumab | joint damage

New Arthritis Drug Prevents Joint Damage


A potential rheumatoid arthritis treatment from French drugmaker Sanofi and its U.S. development partner Regeneron Pharmaceuticals Inc. fared better than a fake drug at improving disease signs and symptoms in a late-stage study.
 
The companies said Friday they saw a statistically significant improvement in patient groups that received their drug, sarilumab, combined with methotrexate compared to those who just received methotrexate and a placebo.
 
About 1,200 patients enrolled in the study. Researchers tested two doses of the drug in adults with active rheumatoid arthritis who were not helped by methotrexate.

Editor's note: 3 Signs You’re Close to a Heart Attack
 
Aside from improving signs and symptoms, the treatment also helped physical function and inhibited joint damage progression, the companies said.
 
Rheumatoid arthritis is a chronic inflammatory disease that affects the joints and destroys soft tissue, cartilage and bone. It represents a major area of research for drug companies because it is chronic, meaning patients will likely take the drugs regularly for a long time.
 
Last year, the Food and Drug Administration approved a new treatment for the disease, Pfizer Inc.'s twice-a-day pill Xeljanz.
 

© Copyright 2015 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

1Like our page
2Share
Health-News
A potential rheumatoid arthritis treatment from French drugmaker Sanofi and its U.S. development partner Regeneron Pharmaceuticals Inc. fared better than a fake drug at improving disease signs and symptoms in a late-stage study. The companies said Friday they saw a...
rheumatoid arthritis,arthritis drug,sarilumab,joint damage
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved